Naphazoline: Difference between revisions
Brian Blank (talk | contribs) No edit summary |
m Protected "Naphazoline": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
(No difference)
|
Revision as of 19:33, 27 September 2011
Clinical data | |
---|---|
Routes of administration | Topical |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C14H14N2 |
Molar mass | 210.274 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Naphazoline (in the hydrochloride form) is the common name for 2-(1-Naphthylmethyl)-2-imidazoline hydrochloride, It is a sympathomimetic agent with marked alpha adrenergic activity. It is a vasoconstrictor with a rapid action in reducing swelling when applied to mucous membrane. It acts on alpha-receptors in the arterioles of the conjunctiva to produce constriction, resulting in decreased congestion. It is an active ingredient in Naphcon-A and Clearine eye drops. It has the molecular formula C14H14N2.HCl and a molecular weight of 246.73 g/mol.
Warnings and contraindications
These apply to all naphazoline-containing substances intended for medicinal use. A few warnings and contraindications are:-
1.Hypersensitivity to Naphazoline.
2.Patients taking MAO inhibitors can experience a severe hypertensive (see hypertension) crisis if given a sympathomimetic drug such as naphazoline HCl.
3.Use in infants and children can result in CNS depression, leading to coma and marked reduction in body temperature.
4.Should be used with caution in patients with severe cardiovascular disease including cardiac arrythmia and in patients with diabetes, especially those with a tendency toward diabetic ketoacidosis.
5 Drug interactions can occur with anaesthetics that sensitize the myocardium to sympathomimetics (e.g cyclopropane or halothane cautiously.
6.Exercise caution when applying prior to use of phenylephrine.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Decongestants
- Imidazolines